Cargando…

Pharmacogenetics of Risperidone and Cardiovascular Risk in Children and Adolescents

Objective. To identify the frequency of obesity and metabolic complications in child and adolescent users of risperidone. Potential associations with clinical parameters and SNPs of the HTR2C, DRD2, LEP, LEPR, MC4R, and CYP2D6 genes were analyzed. Methods. Samples from 120 risperidone users (8–20 ye...

Descripción completa

Detalles Bibliográficos
Autores principales: Dos Santos-Júnior, Amilton, Henriques, Taciane Barbosa, de Mello, Maricilda Palandi, Della Torre, Osmar Henrique, Paes, Lúcia Arisaka, Ferreira-Neto, Adriana Perez, Sewaybricker, Letícia Esposito, Fontana, Thiago Salum, Celeri, Eloisa Helena Rubello Valler, Guerra-Júnior, Gil, Dalgalarrondo, Paulo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4736591/
https://www.ncbi.nlm.nih.gov/pubmed/26880915
http://dx.doi.org/10.1155/2016/5872423
_version_ 1782413313205862400
author Dos Santos-Júnior, Amilton
Henriques, Taciane Barbosa
de Mello, Maricilda Palandi
Della Torre, Osmar Henrique
Paes, Lúcia Arisaka
Ferreira-Neto, Adriana Perez
Sewaybricker, Letícia Esposito
Fontana, Thiago Salum
Celeri, Eloisa Helena Rubello Valler
Guerra-Júnior, Gil
Dalgalarrondo, Paulo
author_facet Dos Santos-Júnior, Amilton
Henriques, Taciane Barbosa
de Mello, Maricilda Palandi
Della Torre, Osmar Henrique
Paes, Lúcia Arisaka
Ferreira-Neto, Adriana Perez
Sewaybricker, Letícia Esposito
Fontana, Thiago Salum
Celeri, Eloisa Helena Rubello Valler
Guerra-Júnior, Gil
Dalgalarrondo, Paulo
author_sort Dos Santos-Júnior, Amilton
collection PubMed
description Objective. To identify the frequency of obesity and metabolic complications in child and adolescent users of risperidone. Potential associations with clinical parameters and SNPs of the HTR2C, DRD2, LEP, LEPR, MC4R, and CYP2D6 genes were analyzed. Methods. Samples from 120 risperidone users (8–20 years old) were collected and SNPs were analyzed, alongside assessment of chronological and bone ages, prescribed and weight-adjusted doses, use of other psychotropic drugs, waist circumference, BMI z-scores, blood pressure, HOMA-IR index, fasting levels of serum glucose, insulin, cholesterol, triglycerides, transaminases, and leptin. Results. Thirty-two (26.7%) patients were overweight and 5 (4.2%) obese. Hypertension was recorded in 8 patients (6.7%), metabolic syndrome in 6 (5%), and increased waist circumference in 20 (16.7%). The HOMA-IR was high for 22 patients (18.3%), while total cholesterol and triglycerides were high in 20 (16.7%) and 41 (34.2%) patients, respectively. SNP associations were found for LEP, HTR2C, and CYP2D6 with BMI; CYP2D6 with blood pressure, ALT, and HOMA-IR; HTR2C and LEPR with leptin levels; MC4R and DRD2 with HOMA-IR; HTR2C with WC; and LEP with ALT. Conclusions. Although not higher than in the general pediatric population, a high frequency of patients was overweight/obese, with abnormalities in metabolic parameters and some pharmacogenetic associations.
format Online
Article
Text
id pubmed-4736591
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-47365912016-02-15 Pharmacogenetics of Risperidone and Cardiovascular Risk in Children and Adolescents Dos Santos-Júnior, Amilton Henriques, Taciane Barbosa de Mello, Maricilda Palandi Della Torre, Osmar Henrique Paes, Lúcia Arisaka Ferreira-Neto, Adriana Perez Sewaybricker, Letícia Esposito Fontana, Thiago Salum Celeri, Eloisa Helena Rubello Valler Guerra-Júnior, Gil Dalgalarrondo, Paulo Int J Endocrinol Research Article Objective. To identify the frequency of obesity and metabolic complications in child and adolescent users of risperidone. Potential associations with clinical parameters and SNPs of the HTR2C, DRD2, LEP, LEPR, MC4R, and CYP2D6 genes were analyzed. Methods. Samples from 120 risperidone users (8–20 years old) were collected and SNPs were analyzed, alongside assessment of chronological and bone ages, prescribed and weight-adjusted doses, use of other psychotropic drugs, waist circumference, BMI z-scores, blood pressure, HOMA-IR index, fasting levels of serum glucose, insulin, cholesterol, triglycerides, transaminases, and leptin. Results. Thirty-two (26.7%) patients were overweight and 5 (4.2%) obese. Hypertension was recorded in 8 patients (6.7%), metabolic syndrome in 6 (5%), and increased waist circumference in 20 (16.7%). The HOMA-IR was high for 22 patients (18.3%), while total cholesterol and triglycerides were high in 20 (16.7%) and 41 (34.2%) patients, respectively. SNP associations were found for LEP, HTR2C, and CYP2D6 with BMI; CYP2D6 with blood pressure, ALT, and HOMA-IR; HTR2C and LEPR with leptin levels; MC4R and DRD2 with HOMA-IR; HTR2C with WC; and LEP with ALT. Conclusions. Although not higher than in the general pediatric population, a high frequency of patients was overweight/obese, with abnormalities in metabolic parameters and some pharmacogenetic associations. Hindawi Publishing Corporation 2016 2016-01-06 /pmc/articles/PMC4736591/ /pubmed/26880915 http://dx.doi.org/10.1155/2016/5872423 Text en Copyright © 2016 Amilton Dos Santos-Júnior et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Dos Santos-Júnior, Amilton
Henriques, Taciane Barbosa
de Mello, Maricilda Palandi
Della Torre, Osmar Henrique
Paes, Lúcia Arisaka
Ferreira-Neto, Adriana Perez
Sewaybricker, Letícia Esposito
Fontana, Thiago Salum
Celeri, Eloisa Helena Rubello Valler
Guerra-Júnior, Gil
Dalgalarrondo, Paulo
Pharmacogenetics of Risperidone and Cardiovascular Risk in Children and Adolescents
title Pharmacogenetics of Risperidone and Cardiovascular Risk in Children and Adolescents
title_full Pharmacogenetics of Risperidone and Cardiovascular Risk in Children and Adolescents
title_fullStr Pharmacogenetics of Risperidone and Cardiovascular Risk in Children and Adolescents
title_full_unstemmed Pharmacogenetics of Risperidone and Cardiovascular Risk in Children and Adolescents
title_short Pharmacogenetics of Risperidone and Cardiovascular Risk in Children and Adolescents
title_sort pharmacogenetics of risperidone and cardiovascular risk in children and adolescents
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4736591/
https://www.ncbi.nlm.nih.gov/pubmed/26880915
http://dx.doi.org/10.1155/2016/5872423
work_keys_str_mv AT dossantosjunioramilton pharmacogeneticsofrisperidoneandcardiovascularriskinchildrenandadolescents
AT henriquestacianebarbosa pharmacogeneticsofrisperidoneandcardiovascularriskinchildrenandadolescents
AT demellomaricildapalandi pharmacogeneticsofrisperidoneandcardiovascularriskinchildrenandadolescents
AT dellatorreosmarhenrique pharmacogeneticsofrisperidoneandcardiovascularriskinchildrenandadolescents
AT paesluciaarisaka pharmacogeneticsofrisperidoneandcardiovascularriskinchildrenandadolescents
AT ferreiranetoadrianaperez pharmacogeneticsofrisperidoneandcardiovascularriskinchildrenandadolescents
AT sewaybrickerleticiaesposito pharmacogeneticsofrisperidoneandcardiovascularriskinchildrenandadolescents
AT fontanathiagosalum pharmacogeneticsofrisperidoneandcardiovascularriskinchildrenandadolescents
AT celerieloisahelenarubellovaller pharmacogeneticsofrisperidoneandcardiovascularriskinchildrenandadolescents
AT guerrajuniorgil pharmacogeneticsofrisperidoneandcardiovascularriskinchildrenandadolescents
AT dalgalarrondopaulo pharmacogeneticsofrisperidoneandcardiovascularriskinchildrenandadolescents